Shareholder pressures Capricor; Lilly dives deeper into vaccines

Kaos Capital wants a "governance reset" to alter the Duchenne cell therapy maker's strategic course. Elsewhere, Bristol Myers furthered efforts to build an "AI-powered" discovery engine.